Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237393 | 0.86 | HPGD (0.50) | NR4A2FFAR1CYP1A2ALDH1A1HPGD | |
| SCHEMBL2087071 | 0.85 | NPC1 (0.49) | EGFRRAB9ASMN1; SMN2ALDH1A1HTT | |
| Potassium SCHEMBL2089657 | 0.85 | HPGD (0.49) | NR4A2FFAR1CYP1A2ALDH1A1HPGD | |
| SCHEMBL2088037 | 0.85 | HPGD (0.49) | NR4A2FFAR1CYP1A2ALDH1A1HPGD | |
| SCHEMBL2089649 | 0.85 | HPGD (0.49) | NR4A2FFAR1CYP1A2ALDH1A1HPGD | |
| SCHEMBL2088041 | 0.85 | HPGD (0.49) | NR4A2FFAR1CYP1A2ALDH1A1HPGD | |
| SCHEMBL2086626 | 0.84 | MAOB (0.68) | KMT2AEGFRNR4A2FFAR1FFAR4 | |
| SCHEMBL9512764 | 0.83 | NR4A2 (0.60) | NR4A2RAB9ASMN1; SMN2MAOBNPC1 | |
| SCHEMBL958298 | 0.83 | NR4A2 (0.49) | KMT2AEGFRNR4A2FFAR1CYP1A2 | |
| SCHEMBL2089424 | 0.80 | MAOB (0.69) | SMN1; SMN2LMNAALDH1A1HTTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461323-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2013-10-09 | — | — | EP | claimed |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-03 | — | — | US | claimed |
| US-8487000-B2 | 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis | Wellstat Therapertics Corporation (US) | 2013-07-16 | — | — | US | claimed |
| JP-4711621-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-01-20 | — | — | US | claimed |
| EP-2268141-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009151695-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-12-17 | — | — | WO | claimed |
| US-20050090555-A1 | Compound for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2005-04-28 | — | — | US | claimed |
| US-20040242692-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-12-02 | — | — | US | claimed |
| EP-1461323-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2004-09-29 | — | — | EP | claimed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | claimed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | claimed |
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-2268141-B1 | COMPOUND AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2019-05-08 | — | — | EP | disclosed |
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | disclosed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | KMT2A 3364/4885EGFR 3857/4885NR4A2 2849/4885 |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | RCC2, HAX1, SLC10A6 | KMT2A 1121/4885EGFR 2760/4885NR4A2 1494/4885 |
| US-20050090555-A1 | Compound for the treatment of metabolic disorders | GOT2, OAT, GPR119 | KMT2A 3442/4885EGFR 4278/4885NR4A2 2462/4885 |
| US-20040242692-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | KMT2A 3364/4885EGFR 3857/4885NR4A2 2849/4885 |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | UGP2, TAS2R46, PYCARD | KMT2A 4176/4885EGFR 4498/4885NR4A2 1952/4885 |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | KMT2A 3364/4885EGFR 3857/4885NR4A2 2849/4885 |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | KMT2A 3364/4885EGFR 3857/4885NR4A2 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.